Incyte Corp [INCY] stock is trading at $74.95, down -0.41%. An important factor to consider is whether the stock is rising or falling in short-term value. The INCY shares have gain 1.60% over the last week, with a monthly amount glided 4.23%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Incyte Corp [NASDAQ: INCY] stock has seen the most recent analyst activity on December 17, 2024, when UBS initiated its Neutral rating and assigned the stock a price target of $77. Previously, BofA Securities upgraded its rating to Buy on October 29, 2024, and elevated its price target to $90. On October 01, 2024, Wolfe Research initiated with a Outperform rating and assigned a price target of $84 on the stock. Truist downgraded its rating to a Hold and decreased its price target to $74 on September 18, 2024. BMO Capital Markets downgraded its rating to a Underperform and reduced its price target to $48 on July 02, 2024. Deutsche Bank started tracking with a Hold rating for this stock on May 23, 2024, and assigned it a price target of $55. In a note dated April 23, 2024, Cantor Fitzgerald initiated an Neutral rating.
Incyte Corp [INCY] stock has fluctuated between $50.35 and $83.95 over the past year. Currently, Wall Street analysts expect the stock to reach $99.57 within the next 12 months. Incyte Corp [NASDAQ: INCY] shares were valued at $74.95 at the most recent close of the market. An investor can expect a potential return of 32.85% based on the average INCY price forecast.
Analyzing the INCY fundamentals
Incyte Corp [NASDAQ:INCY] reported sales of 4.08B for the trailing twelve months, which represents a growth of 23.81%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.01%, Pretax Profit Margin comes in at 0.07%, and Net Profit Margin reading is 0.01%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.01 and Total Capital is -0.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 74.23 points at the first support level, and at 73.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 75.58, and for the 2nd resistance point, it is at 76.21.
Ratios To Look Out For
For context, Incyte Corp’s Current Ratio is 1.87. On the other hand, the Quick Ratio is 1.82, and the Cash Ratio is 0.87. Considering the valuation of this stock, the price to sales ratio is 3.54, the price to book ratio is 4.56 and price to earnings (TTM) ratio is 530.81.
Transactions by insiders
Recent insider trading involved Stein Steven H, EVP & Chief Medical Officer, that happened on Jan 21 ’25 when 12352.0 shares were sold. Officer, STEVEN STEIN completed a deal on Jan 21 ’25 to buy 12352.0 shares. Meanwhile, Principal Accounting Officer Tray Thomas sold 650.0 shares on Dec 13 ’24.
